Not only does doxorubicin drive chemoresistance in triple-negative BC cells through CXCR2 and TGF-β upregulation but also induces drug resistance by interacting with other signaling pathways that promote drug resistance, such as MAPK/ERK, PI3K/Akt (Christowitz et al., 2019), and NF-kB, as reported by some studies (Marinello et al., 2019). The gene discussed is AKT1; the disease is breast cancer.